Four More Experimental Ebola Treatments Approved for Use in Congo

Four more experimental treatments for Ebola virus have been approved by the Congo health ministry for use in an outbreak of the deadly infectious disease in the country's northeast.

The treatments are ZMapp, Remdesivir, Favipiravir and Regn3450 - 3471 - 3479. On Aug. 11, health officials began using the experimental treatment mAb114 on 10 patients, and the ministry says they are doing well, the Associated Press reported.

The most recent Ebola outbreak in Congo was declared in Mangina in North Kivu province on Aug. 1. There have been 75 confirmed Ebola cases and 27 probable ones. Of 59 reported deaths, 32 have been confirmed as Ebola, according to the health ministry.

It said that since Aug. 8, more than 1,600 people have been vaccinated in Mabalako and Beni in North Kivu province and in Mandima in Ituri province, the AP reported.

Ebola is spread via contact with bodily fluids of infected people. Depending on the strain, it can be fatal in up to 90 percent of cases.

Copyright © 2018 HealthDay. All rights reserved.


Bacterial Infections 101: Types, Symptoms, and Treatments See Slideshow

Health Solutions From Our Sponsors